Accelovance Announces Second Office in China: Shanghai

    SHANGHAI, China, Nov. 9 /PRNewswire/ -- Accelovance, a Rockville, Maryland
 based company with a wholly foreign owned enterprise (WFOE) in China
 celebrates the opening of an office in Shanghai, its second in the PR China.
 With additional presence in China's pharmaceutical market, the Shanghai office
 allows Accelovance to broaden its services and expand its capacity for
 conducting Phase I-IV clinical trials.
     "Accelovance has a growing presence as a full service contract research
 organization (CRO) in China and the opening of a new office is evidence of
 that. It gives us a greater opportunity to service pharma and biotech
 companies on an international level," commented President and CEO Stephen J.
 Trevisan.  Accelovance will take office space with the State of Maryland in
 Shanghai, immediately employing 3-5 clinical personnel.  In recent years, the
 State of Maryland has proactively worked with locally based companies to
 promote growth in emerging markets, such as China.  Mary Kane, Maryland's
 Secretary of State, agrees, "Maryland has embraced the idea of global
 cooperative ventures.  Accelovance is an excellent example of future
 opportunities for the business community in Maryland and abroad."
     Accelovance's Beijing office will continue to serve as the base of
 operations for China, managing the new Shanghai location.  Operations in China
 provide Accelovance's clients with a strategic alternative to their clinical
 trial needs and add to the capabilities of an existing 10-site network in the
 United States.  Dr. Ken Ren, President of Accelovance China noted, "Since our
 Beijing office opened in May, our services in China have been well received.
 Now with a location in another region of the country, Accelovance is better
 positioned to rapidly enroll patients and conduct trials in a cost effective
 manner."
 
     Headquartered in Rockville, Maryland, Accelovance is a privately held
 company that has 10 clinical sites in the United States.  In China, the
 Company operates through its wholly owned foreign enterprise in Beijing and
 has established clinical services in the country.  Globally, Accelovance
 provides Phase I-IV clinical trial services across a focus of therapeutic
 areas that include investigator selection, patient recruitment and study
 management services for pharmaceutical, contract research organization (CRO),
 and biotechnology industries. The company is focused on optimizing the quality
 and productivity of multiple clinical sites, through strong central management
 and targeted pro-active patient recruitment.  Delivering high quality and
 timely clinical trial support services, Accelovance is committed to
 understanding and meeting its clients needs to ensure their success.
     For more information, visit the company's website at
 http://www.accelovance.com.
 
     CONTACT: Garrett D. Smith at 240.238.4914.
 
 

SOURCE  Accelovance